Summary of opinion: Opdivo, 25/04/2024 Positive
On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Opdivo. The marketing authorisation holder for this …